BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21920196)

  • 1. Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center.
    Bastianelli C; Farris M; Benagiano G
    Contraception; 2011 Oct; 84(4):402-8. PubMed ID: 21920196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirena, an Italian experience.
    Bastianelli C; Farris M; Rapiti S
    Minerva Ginecol; 2011 Aug; 63(4):343-9. PubMed ID: 21747343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding.
    Busfield RA; Farquhar CM; Sowter MC; Lethaby A; Sprecher M; Yu Y; Sadler LC; Brown P; Johnson N
    BJOG; 2006 Mar; 113(3):257-63. PubMed ID: 16487195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Rowe PJ
    Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
    Andrade A; Wildemeersch D
    Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
    Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
    Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up.
    Chi C; Huq FY; Kadir RA
    Contraception; 2011 Mar; 83(3):242-7. PubMed ID: 21310286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
    Rose S; Chaudhari A; Peterson CM
    Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The levonorgestrel intrauterine system in the management of menorrhagia.
    Barrington JW; Bowen-Simpkins P
    Br J Obstet Gynaecol; 1997 May; 104(5):614-6. PubMed ID: 9166207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
    Reid PC; Virtanen-Kari S
    BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
    Lukes AS; Reardon B; Arepally G
    Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.
    Lehtovirta P; Paavonen J; Heikinheimo O
    Contraception; 2007 Jan; 75(1):37-9. PubMed ID: 17161122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system--Mirena.
    Skrzypulec V; Drosdzol A
    Coll Antropol; 2008 Dec; 32(4):1059-68. PubMed ID: 19149209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J; Aldrighi JM; de Lima GR
    Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
    Mansour D
    Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
    Kelekci S; Kelekci KH; Yilmaz B
    Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.